Univentis Medicare Limited

Univentis Medicare Limited is an Indian pharmaceutical company established on July 3, 2015, in Panvel, Maharashtra. The company is registered under the Corporate Identification Number (CIN) U24232MH2015PLC402722. It operates as a public unlisted company with an authorized capital of ₹5 million and a paid-up capital of ₹1.5 million. The registered office is located at Plot No. L6, MIDC Road, Taloja, Panvel, Maharashtra 410208, India.

Univentis Medicare Limited specializes in the marketing and sale of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio is concentrated in the Advanced Antibiotics therapeutic category, with its top two products being Ceftriaxone and Cefixime, accounting for 100% of its export value. As of March 2026, the company employs approximately 96 professionals.

The company's manufacturing operations are primarily based in Baddi, Himachal Pradesh, where its holding company, Innova Captab Limited, operates three manufacturing units. These facilities are licensed to manufacture products through two state-of-the-art manufacturing plants, adhering to WHO-GMP and EU-GMP standards.

The leadership team of Univentis Medicare Limited includes:

• Manoj Kumar Lohariwala – Director
• Vinay Kumar Lohariwala – Director
• Anup Agarwal – Director
• Riteshe Paltani – Whole-Time Director (appointed May 19, 2025)
• Mahendar Korthiwada – Director (appointed April 28, 2022)

These individuals are responsible for the strategic direction and operational management of the company.

Univentis Medicare Limited's export activities are primarily focused on the Advanced Antibiotics category, with significant exports of Ceftriaxone and Cefixime. The company has engaged in 161 shipments totaling $8.1 million in export value. However, specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly available. The company's concentration in a single therapeutic category and reliance on two products for its export revenue may pose risks related to market diversification and regulatory approvals.

Univentis Medicare Limited's export data does not provide specific information on its presence in emerging markets such as Africa, Latin America, and Southeast Asia. The company's focus on Advanced Antibiotics suggests potential opportunities in these regions, especially if it holds WHO prequalification or other relevant certifications. However, without explicit data on regulatory approvals and market access, a comprehensive assessment of its position in these markets cannot be made.

The company's export strategy appears to be concentrated in the Advanced Antibiotics category, with a portfolio heavily reliant on Ceftriaxone and Cefixime. This lack of diversification may expose Univentis Medicare Limited to risks associated with market fluctuations and regulatory changes in the antibiotic sector. A more diversified product portfolio and expansion into additional therapeutic areas could mitigate these risks and enhance the company's strategic position.

Specific information regarding Univentis Medicare Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export data does not indicate shipments to the United States, suggesting limited or no market presence in the U.S. Without FDA approvals, the company may face challenges in entering or expanding within the U.S. pharmaceutical market.

Univentis Medicare Limited's holding company, Innova Captab Limited, operates manufacturing facilities that maintain WHO-GMP and EU-GMP certifications. These certifications are essential for ensuring product quality and compliance with international standards. However, specific details regarding WHO prequalification or EDQM status for Univentis Medicare Limited's products are not publicly available.

Univentis Medicare Limited is registered with the Ministry of Corporate Affairs under CIN U24232MH2015PLC402722. The company's manufacturing facilities are licensed to produce pharmaceutical products in compliance with Indian regulations. However, specific details regarding approvals from the Central Drugs Standard Control Organisation (CDSCO), state drug controllers, and export No Objection Certificates (NOCs) are not publicly available.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts issued to Univentis Medicare Limited. The absence of such information suggests that the company has maintained compliance with regulatory standards.

Univentis Medicare Limited operates in the competitive Advanced Antibiotics segment, with its top products being Ceftriaxone and Cefixime. While specific market share data is not available, the company's reliance on a limited product portfolio may impact its competitive positioning. Diversifying its product range and expanding into additional therapeutic areas could enhance its competitiveness in the global pharmaceutical market.

Univentis Medicare Limited's key differentiators include its focus on high-quality, affordable medicines and its adherence to international manufacturing standards such as WHO-GMP and EU-GMP. These factors contribute to the company's reputation for quality and reliability in the pharmaceutical industry.

Univentis Medicare Limited's current strategic direction appears to be centered on the production and export of Advanced Antibiotics, particularly Ceftriaxone and Cefixime. The company's future outlook would benefit from diversifying its product portfolio, exploring new therapeutic areas, and expanding its presence in regulated markets to enhance growth and mitigate risks associated with market concentration.

Univentis Medicare Limited's export data indicates a total export value of $8.1 million across 161 shipments, with a portfolio concentrated in the Advanced Antibiotics category. The company's adherence to WHO-GMP and EU-GMP standards reflects a commitment to quality manufacturing. However, the lack of diversification in its product portfolio and limited market presence in certain regions may impact its reliability as a supplier.

Importers should verify the following certifications to ensure product quality and compliance:

• WHO-GMP Certification: Confirms adherence to World Health Organization Good Manufacturing Practices. Verification can be done through the WHO official website or by contacting the manufacturer directly.

• EU GMP Certification: Indicates compliance with European Union Good Manufacturing Practices. Verification can be conducted through the European Medicines Agency (EMA) or by reaching out to the manufacturer.

• FDA Approval: For U.S. market access, ensure that the manufacturer holds FDA approvals for the specific products. This can be verified through the FDA's official website or by contacting the manufacturer.

When considering Univentis Medicare Limited as a supplier, importers should undertake the following verification steps:

• Product Quality Verification: Request copies of WHO-GMP and EU-GMP certificates.

• Regulatory Compliance: Confirm FDA approvals for products intended for the U.S. market.

• Financial Stability: Review the company's financial statements to assess financial health.

• Market Presence: Evaluate the company's presence and reputation in target markets.

• Supply Chain Reliability: Assess the company's ability to meet delivery schedules and quality standards.

Red flags to watch for include a lack of diversification in the product portfolio, limited market presence in key regions, and absence of necessary regulatory approvals for target markets.

Recommended pre-order checks involve verifying the authenticity of certifications, assessing the company's compliance history, and evaluating the quality control measures in place to ensure product safety and efficacy.